{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:36:17Z","timestamp":1790742977919,"version":"4.1.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,12,15]],"date-time":"2020-12-15T00:00:00Z","timestamp":1607990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,12,15]],"date-time":"2020-12-15T00:00:00Z","timestamp":1607990400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Parkinsons Dis."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Management of apathy, depression and anxiety in Parkinson\u2019s disease (PD) represents a challenge. Dopamine agonists have been suggested to be effective. This multicenter, randomized (1:1), double-blind study assessed the 6-month effect of rotigotine versus placebo on apathy, depression and anxiety in de novo PD. The primary outcome was the change of apathy, measured with the LARS. The secondary outcomes were the change in depression and anxiety, measured with BDI-2 and STAI-trait and state. Forty-eight drug-naive PD patients were included. The primary outcome was not reached, with a surprisingly high placebo effect on apathy (60%). There was no significant difference in the change of depression at 6 months between rotigotine and placebo. Trait-anxiety was significantly improved by rotigotine compared to placebo (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.04). Compared to placebo, low dose rotigotine significantly improved trait anxiety, but not apathy and depression. The major placebo effect on apathy points towards the importance of a multidisciplinary and tight follow-up in the management of neuropsychiatric symptoms.\n                  <\/jats:p>","DOI":"10.1038\/s41531-020-00142-x","type":"journal-article","created":{"date-parts":[[2020,12,15]],"date-time":"2020-12-15T06:08:06Z","timestamp":1608012486000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["A randomized controlled double-blind study of rotigotine on neuropsychiatric symptoms in de novo PD"],"prefix":"10.1038","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2385-7096","authenticated-orcid":false,"given":"A.","family":"Castrioto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Thobois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Anheim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. L.","family":"Quesada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Lhomm\u00e9e","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Klinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Bichon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Schmitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Durif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. P.","family":"Azulay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. L.","family":"Houeto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Longato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Philipps","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Pelissier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Broussolle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Moro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Tranchant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4473-9993","authenticated-orcid":false,"given":"V.","family":"Fraix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Krack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the Honeymoon study group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,12,15]]},"reference":[{"key":"142_CR1","doi-asserted-by":"publisher","first-page":"659","DOI":"10.3233\/JPD-150604","volume":"5","author":"D Aarsland","year":"2015","unstructured":"Aarsland, D. & Kramberger, M. G. Neuropsychiatric symptoms in Parkinson\u2019s disease. J. Parkinsons Dis. 5, 659\u2013667 (2015).","journal-title":"J. Parkinsons Dis."},{"key":"142_CR2","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1002\/mds.26587","volume":"31","author":"A Castrioto","year":"2016","unstructured":"Castrioto, A., Thobois, S., Carnicella, S., Maillet, A. & Krack, P. Emotional manifestations of PD: neurobiological basis. Mov. Disord. 31, 1103\u20131113 (2016).","journal-title":"Mov. Disord."},{"key":"142_CR3","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1002\/mds.26208","volume":"30","author":"MG den Brok","year":"2015","unstructured":"den Brok, M. G. et al. Apathy in Parkinson\u2019s disease: a systematic review and meta-analysis. Mov. Disord. 30, 759\u2013769 (2015).","journal-title":"Mov. Disord."},{"key":"142_CR4","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/S1474-4422(15)00019-8","volume":"14","author":"J Pagonabarraga","year":"2015","unstructured":"Pagonabarraga, J., Kulisevsky, J., Strafella, A. P. & Krack, P. Apathy in Parkinson\u2019s disease: clinical features, neural substrates, diagnosis, and treatment. Lancet Neurol. 14, 518\u2013531 (2015).","journal-title":"Lancet Neurol."},{"key":"142_CR5","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1002\/mds.26058","volume":"29","author":"K Dujardin","year":"2014","unstructured":"Dujardin, K. et al. Apathy in untreated early-stage Parkinson disease: relationship with other non-motor symptoms. Mov. Disord. 29, 1796\u20131801 (2014).","journal-title":"Mov. Disord."},{"key":"142_CR6","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1136\/jnnp.2008.166959","volume":"80","author":"D Aarsland","year":"2009","unstructured":"Aarsland, D. et al. The spectrum of neuropsychiatric symptoms in patients with early untreated Parkinson\u2019s disease. J. Neurol. Neurosurg. Psychiatry 80, 928\u2013930 (2009).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"142_CR7","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s00415-009-5297-x","volume":"257","author":"KF Pedersen","year":"2010","unstructured":"Pedersen, K. F. et al. Apathy in drug-na\u00efve patients with incident Parkinson\u2019s disease: the Norwegian ParkWest study. J. Neurol. 257, 217\u2013223 (2010).","journal-title":"J. Neurol."},{"key":"142_CR8","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1136\/jnnp-2018-318265","volume":"90","author":"C Le Heron","year":"2019","unstructured":"Le Heron, C., Holroyd, C. B., Salamone, J. & Husain, M. Brain mechanisms underlying apathy. J. Neurol. Neurosurg. Psychiatry 90, 302\u2013312 (2019).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"142_CR9","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1093\/brain\/awh445","volume":"128","author":"P Remy","year":"2005","unstructured":"Remy, P., Doder, M., Lees, A., Turjanski, N. & Brooks, D. Depression in Parkinson\u2019s disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain 128, 1314\u20131322 (2005).","journal-title":"Brain"},{"key":"142_CR10","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1093\/brain\/awq032","volume":"133","author":"S Thobois","year":"2010","unstructured":"Thobois, S. et al. Non-motor dopamine withdrawal syndrome after surgery for Parkinson\u2019s disease: predictors and underlying mesolimbic denervation. Brain 133, 1111\u20131127 (2010).","journal-title":"Brain"},{"key":"142_CR11","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1093\/brain\/awt067","volume":"136","author":"S Thobois","year":"2013","unstructured":"Thobois, S. et al. Parkinsonian apathy responds to dopaminergic stimulation of D2\/D3 receptors with piribedil. Brain 136, 1568\u20131577 (2013).","journal-title":"Brain"},{"key":"142_CR12","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1016\/S0028-3932(02)00108-2","volume":"40","author":"V Czernecki","year":"2002","unstructured":"Czernecki, V. et al. Motivation, reward, and Parkinson\u2019s disease: influence of dopatherapy. Neuropsychologia 40, 2257\u20132267 (2002).","journal-title":"Neuropsychologia"},{"key":"142_CR13","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.parkreldis.2017.08.008","volume":"44","author":"H Liu","year":"2017","unstructured":"Liu, H. et al. Apathy in drug-na\u00efve patients with Parkinson\u2019s disease. Parkinsonism Relat. Disord. 44, 28\u201332 (2017).","journal-title":"Parkinsonism Relat. Disord."},{"key":"142_CR14","doi-asserted-by":"publisher","first-page":"S42","DOI":"10.1002\/mds.23884","volume":"26","author":"K Seppi","year":"2011","unstructured":"Seppi, K. et al. The movement disorder society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson\u2019s disease. Mov. Disord. 26, S42\u2013S80 (2011).","journal-title":"Mov. Disord."},{"key":"142_CR15","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1093\/brain\/aww162","volume":"139","author":"A Maillet","year":"2016","unstructured":"Maillet, A. et al. The prominent role of serotonergic degeneration in apathy, anxiety and depression in de novo Parkinson\u2019s disease. Brain 139, 2486\u20132502 (2016).","journal-title":"Brain"},{"key":"142_CR16","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/S1474-4422(19)30140-1","volume":"18","author":"H Wilson","year":"2019","unstructured":"Wilson, H. et al. Serotonergic pathology and disease burden in the premotor and motor phase of A53T \u03b1-synuclein parkinsonism: a cross-sectional study. Lancet Neurol. 18, 748\u2013759 (2019).","journal-title":"Lancet Neurol."},{"key":"142_CR17","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1136\/jnnp-2013-306439","volume":"85","author":"D Devos","year":"2014","unstructured":"Devos, D. et al. Rivastigmine in apathetic but dementia and depression-free patients with Parkinson\u2019s disease: a double-blind, placebo-controlled, randomised clinical trial. J. Neurol. Neurosurg. Psychiatry 85, 668\u2013674 (2014).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"142_CR18","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1002\/mds.26170","volume":"30","author":"D Weintraub","year":"2015","unstructured":"Weintraub, D. et al. Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson\u2019s disease. Mov. Disord. 30, 919\u2013927 (2015).","journal-title":"Mov. Disord."},{"key":"142_CR19","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/S1474-4422(10)70106-X","volume":"9","author":"P Barone","year":"2010","unstructured":"Barone, P. et al. Pramipexole for the treatment of depressive symptoms in patients with Parkinson\u2019s disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 9, 573\u2013580 (2010).","journal-title":"Lancet Neurol."},{"key":"142_CR20","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.neurol.2009.06.003","volume":"165","author":"C Ardouin","year":"2009","unstructured":"Ardouin, C. et al. Assessment of hyper- and hypodopaminergic behaviors in Parkinson\u2019s disease. Rev. Neurol. 165, 845\u2013856 (2009).","journal-title":"Rev. Neurol."},{"key":"142_CR21","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/S1474-4422(07)70108-4","volume":"6","author":"WH Poewe","year":"2007","unstructured":"Poewe, W. H. et al. Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson\u2019s disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol. 6, 513\u2013520 (2007).","journal-title":"Lancet Neurol."},{"key":"142_CR22","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.parkreldis.2017.06.024","volume":"43","author":"S Rutten","year":"2017","unstructured":"Rutten, S. et al. Predictors of anxiety in early-stage Parkinson\u2019s disease - Results from the first two years of a prospective cohort study. Parkinsonism Relat. Disord. 43, 49\u201355 (2017).","journal-title":"Parkinsonism Relat. Disord."},{"key":"142_CR23","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1002\/mds.26016","volume":"30","author":"D Weintraub","year":"2015","unstructured":"Weintraub, D., David, A. S., Evans, A. H., Grant, J. E. & Stacy, M. Clinical spectrum of impulse control disorders in Parkinson\u2019s disease. Mov. Disord. 30, 121\u2013127 (2015).","journal-title":"Mov. Disord."},{"key":"142_CR24","doi-asserted-by":"publisher","first-page":"267","DOI":"10.3233\/JPD-150747","volume":"6","author":"I Rieu","year":"2016","unstructured":"Rieu, I. et al. Impact of mood and behavioral disorders on quality of life in Parkinson\u2019s disease. J. Parkinsons Dis. 6, 267\u2013277 (2016).","journal-title":"J. Parkinsons Dis."},{"key":"142_CR25","doi-asserted-by":"publisher","first-page":"625","DOI":"10.3233\/JPD-150535","volume":"5","author":"M Sierra","year":"2015","unstructured":"Sierra, M. et al. Apathy and impulse control disorders: Yin & Yang of dopamine dependent behaviors. J. Parkinsons Dis. 5, 625\u2013636 (2015).","journal-title":"J. Parkinsons Dis."},{"key":"142_CR26","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.parkreldis.2013.02.018","volume":"19","author":"RK Chaudhuri","year":"2013","unstructured":"Chaudhuri, R. K. et al. Rotigotine and specific non-motor symptoms of Parkinson\u2019s disease: post hoc analysis of RECOVER. Parkinsonism Relat. Disord. 19, 660\u2013665 (2013).","journal-title":"Parkinsonism Relat. Disord."},{"key":"142_CR27","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1111\/ene.12757","volume":"22","author":"A Antonini","year":"2015","unstructured":"Antonini, A. et al. Effects of rotigotine transdermal patch in patients with Parkinson\u2019s disease presenting with non-motor symptoms - results of a double-blind, randomized, placebo-controlled trial. Eur. J. Neurol. 22, 1400\u20131407 (2015).","journal-title":"Eur. J. Neurol."},{"key":"142_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-016-0610-7","volume":"16","author":"RA Hauser","year":"2016","unstructured":"Hauser, R. A. et al. Evaluation of rotigotine transdermal patch for the treatment of apathy and motor symptoms in Parkinson\u2019s disease. BMC Neurol. 16, 90 (2016).","journal-title":"BMC Neurol."},{"key":"142_CR29","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1080\/00207454.2017.1387111","volume":"128","author":"F Valldeoriola","year":"2018","unstructured":"Valldeoriola, F. et al. The effects of transdermal rotigotine on non-motor symptoms of Parkinson\u2019s disease: a multicentre, observational, retrospective, post-marketing study. Int. J. Neurosci. 128, 369\u2013375 (2018).","journal-title":"Int. J. Neurosci."},{"key":"142_CR30","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.jns.2011.05.045","volume":"310","author":"A Schrag","year":"2011","unstructured":"Schrag, A. Apathy and depression scales in Parkinson\u2019s disease: are they good enough? J. Neurol. Sci. 310, 216\u2013219 (2011).","journal-title":"J. Neurol. Sci."},{"key":"142_CR31","doi-asserted-by":"publisher","first-page":"267","DOI":"10.2217\/nmt-2018-0010","volume":"8","author":"D Mohammad","year":"2018","unstructured":"Mohammad, D. et al. Psychometric properties of apathy scales in Parkinson\u2019s disease: a systematic review. Neurodegener. Dis. Manag. 8, 267\u2013282 (2018).","journal-title":"Neurodegener. Dis. Manag."},{"key":"142_CR32","doi-asserted-by":"publisher","first-page":"31","DOI":"10.11138\/FNeur\/2018.33.1.031","volume":"33","author":"V Valentino","year":"2018","unstructured":"Valentino, V. et al. Apathy in Parkinson\u2019s disease: differences between caregiver\u2019s report and self-evaluation. Funct. Neurol. 33, 31\u201335 (2018).","journal-title":"Funct. Neurol."},{"key":"142_CR33","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1136\/jnnp.2005.075929","volume":"77","author":"P Sockeel","year":"2006","unstructured":"Sockeel, P. et al. The Lille apathy rating scale (LARS), a new instrument for detecting and quantifying apathy: validation in Parkinson\u2019s disease. J. Neurol. Neurosurg. Psychiatry 77, 579\u2013584 (2006).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"142_CR34","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1176\/jnp.4.2.134","volume":"4","author":"SE Starkstein","year":"1992","unstructured":"Starkstein, S. E. et al. Reliability, validity, and clinical correlates of apathy in Parkinson\u2019s disease. J. Neuropsychiatry Clin. Neurosci. 4, 134\u2013139 (1992).","journal-title":"J. Neuropsychiatry Clin. Neurosci."},{"key":"142_CR35","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1002\/mds.26223","volume":"30","author":"I Rieu","year":"2015","unstructured":"Rieu, I. et al. International validation of a behavioral scale in Parkinson\u2019s disease without dementia. Mov. Disord. 30, 705\u2013713 (2015).","journal-title":"Mov. Disord."},{"key":"142_CR36","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1126\/science.1060937","volume":"293","author":"R de la Fuente-Fern\u00e1ndez","year":"2001","unstructured":"de la Fuente-Fern\u00e1ndez, R. et al. Expectation and dopamine release: mechanism of the placebo effect in Parkinson\u2019s disease. Science 293, 1164\u20131166 (2001).","journal-title":"Science"},{"key":"142_CR37","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0050045","volume":"5","author":"I Kirsch","year":"2008","unstructured":"Kirsch, I. et al. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med. 5, e45 (2008).","journal-title":"PLoS Med."},{"key":"142_CR38","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1007\/s00415-018-8761-7","volume":"265","author":"C Eggers","year":"2018","unstructured":"Eggers, C. et al. Patient-centered integrated healthcare improves quality of life in Parkinson\u2019s disease patients: a randomized controlled trial. J. Neurol. 265, 764\u2013773 (2018).","journal-title":"J. Neurol."},{"key":"142_CR39","unstructured":"Mattis, S. Mental status examination for organic mental syndrome in the elderly patient. In: Bellack, L. and Karusu, T.B., Eds., Geriatric Psychiatry, pp 77\u2013121 (Grune & Stratton, New York, 1976)."},{"key":"142_CR40","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1212\/WNL.55.11.1621","volume":"55","author":"B Dubois","year":"2000","unstructured":"Dubois, B., Slachevsky, A., Litvan, I. & Pillon, B. The FAB: a frontal assessment battery at bedside. Neurology 55, 1621\u20131626 (2000).","journal-title":"Neurology"},{"key":"142_CR41","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1002\/mds.22340","volume":"23","author":"CG Goetz","year":"2008","unstructured":"Goetz, C. G. et al. Movement Disorder Society-sponsored revision of the Unified Parkinson\u2019s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov. Disord. 23, 2129\u20132170 (2008).","journal-title":"Mov. Disord."},{"key":"142_CR42","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1207\/s15327752jpa6703_13","volume":"67","author":"AT Beck","year":"1996","unstructured":"Beck, A. T., Steer, R. A., Ball, R. & Ranieri, W. Comparison of Beck Depression Inventories -IA and -II in psychiatric outpatients. J. Pers. Assess. 67, 588\u2013597 (1996).","journal-title":"J. Pers. Assess."},{"key":"142_CR43","volume-title":"Manual for the State-Trait Anxiety Inventory.","author":"CD Spielberger","year":"1983","unstructured":"Spielberger, C. D., Gorsuch, R. L., Lushene, R., Vagg, P. R. & Jacobs, G. A. Manual for the State-Trait Anxiety Inventory. (Consulting Psychologists Press, Palo Alto, CA, 1983)."},{"key":"142_CR44","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1093\/ageing\/26.5.353","volume":"26","author":"C Jenkinson","year":"1997","unstructured":"Jenkinson, C., Fitzpatrick, R., Peto, V., Greenhall, R. & Hyman, N. The Parkinson\u2019s Disease Questionnaire (PDQ\u221239): development and validation of a Parkinson\u2019s disease summary index score. Age Ageing 26, 353\u2013357 (1997).","journal-title":"Age Ageing"}],"container-title":["npj Parkinson's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41531-020-00142-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-020-00142-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-020-00142-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T22:05:05Z","timestamp":1670277905000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41531-020-00142-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,15]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["142"],"URL":"https:\/\/doi.org\/10.1038\/s41531-020-00142-x","relation":{},"ISSN":["2373-8057"],"issn-type":[{"value":"2373-8057","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,15]]},"assertion":[{"value":"10 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C.A.C. reports research grants from France Parkinson Foundation and Medtronic, reimbursement of travel expenses to scientific meetings from ELIVIE, Medtronic and Boston Scientific, honoraria from Novartis for lecturing, outside de submitted work. S.T. reports grants from France Parkinson, FRM, ANR, PHRC, UCB, Neurodis, personal fees from Aguettant, Boston Scientific, Novartis, non-financial support from Zambon, Abbvie, Elivie outside the submitted work. M.A. reports travel grants and\/or honoraria from Actelion Pharmaceuticals, Johnson and Johnson, Teva, LVL, Aguettant, Orkyn, AbbVie and Merz. J.L.Q., E.L., H.K., A.B., E.S., F.D., N.L., C.P., P.P., and E.B. report no relevant disclosure related to this study. J.P.A. reports honoraria for consultancies and advisory boards from Abbvie, Merz, Allergan, Medtronic, Ever Pharma. J.L.H. reports grants from ANR, France Parkinson Foundation, Abbvie, UCB, and honoraria for consultancies and advisory boards from Abbvie, Medtronic, and Zambon. E.M. reports honorarium from Medtronic and Newronica for lecturing, and an educational grant from Boston. C.T. reports reimbursement of travel expenses from Merz, and honoraria from Allergan for lecturing. V.F. reports reimbursement of travel expenses from Merz, AbbVie, honoraria for scientific counseling from AbbVie. P.K. reports a research grant from UCB for the present study, research grants from Swiss National Science Foundation, ROGER DE SPOELBERCH Foundation, Bertarelli Foundation, Annemarie Opprecht Foundation, Parkinson Schweiz, Boston Scientific, and Aleva, lecturing fees paid to employing institution (Inselspital) from Boston Scientific, as well as reimbursement of traveling expenses to scientific meeting by Zambon, outside the submitted work.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"41"}}